JAK1, Janus kinase 1, 3716

N. diseases: 239; N. variants: 41
Disease: Primary Myelofibrosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. 28500170 2017
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Selective JAK1 inhibition alone is unlikely to succeed in myelofibrosis. 28441920 2017
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 GeneticVariation disease BEFREE In this open-label phase II study, we evaluated the efficacy and safety of three dose levels of INCB039110, a potent and selective oral JAK1 inhibitor, in patients with intermediate- or high-risk myelofibrosis and a platelet count ≥50×10<sup>9</sup>/L. 27789678 2017
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Purpose We evaluated the efficacy and safety of momelotinib, a potent and selective Janus kinase 1 and 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients with myelofibrosis. 28930494 2017
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Janus kinase 1/2 (JAK1/2) inhibitor therapy is effective in alleviating myelofibrosis (MF)-related symptoms. 26659587 2016
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis. 25441108 2015
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE JAK1/2 inhibitors have broadened the therapeutic options in myelofibrosis. 25189727 2014
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and symptomatic burden and improved survival in patients with myelofibrosis (MF), irrespective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best available therapy (COMFORT-II). 24458439 2014
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Only one JAK1/JAK2 inhibitor has gained FDA approval for treatment of myelofibrosis. 24766055 2014
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE JAK2 inhibition became a reality with first patients receiving drugs that targeted JAK2 in 2007 and was marked by the first approval in 2011 of Ruxolitinib a JAK 1 and 2-inhibitor to treat myelofibrosis (MF). 25189729 2014
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status. 25193869 2014
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Of these, the JAK1/2 inhibitor, ruxolitinib (INCB018424, Incyte Corporation) was recently approved for the treatment of patients with myelofibrosis (MF). 23670175 2013
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Ruxolitinib is a small-molecule inhibitor of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis. 23307549 2013
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis. 23313046 2013
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematologic malignancies. 23406773 2013
CUI: C0001815
Disease: Primary Myelofibrosis
Primary Myelofibrosis 		0.100 Biomarker disease BEFREE Ruxolitinib is the first JAK1/2 inhibitor approved by the Food and Drug Administration (FDA) for the treatment of patients with intermediate- or high-risk MF. 23042420 2012